
Release date: 2024-08-14 17:23:40 Article From: Lucius Laos Recommended: 427
Venetoclax is the world's only approved selective inhibitor of Bcl-2 that can induce spontaneous apoptosis of cancer cells by specifically binding to Bcl-2 protein and reduce the impact on healthy cells.
Drug interactions are organized as follows:
Concomitant use with strong or moderate CYP3A inhibitors or P-gp inhibitors increases plasma concentrations (Cmax and AUC0-INF) of venetoclax, which may increase the risk of toxicity and increase the likelihood of tumor lysis syndrome (TLS).
warfarin
Venetoclax increases blood levels of warfarin, which may increase the risk of bleeding. Patients taking both drugs require more frequent monitoring of the international normalized ratio (INR).
In other words, special drug users should be aware of the drug.
Patients with reduced renal function are at increased risk of tumor lysis syndrome (TLS) when taking venetoclax and require more rigorous prevention and monitoring. Patients with mild to severe renal insufficiency generally do not need to adjust the dose.
Venetoclax may cause embryo-fetal damage to pregnant women. There are currently no data on the risk of venetoclax in pregnant women, and it is recommended to avoid it during pregnancy.
Patients may experience a range of adverse effects while receiving venetoclax.
Cough may be caused by an infection or medication side effects, and persistent cough may require further evaluation and symptomatic treatment.
Patients may experience pain in the joints, bones, or muscles, often with pain medication or physical therapy to relieve symptoms.
Persistent nausea may affect the patient's appetite and nutritional intake. Anti-nausea medications or dietary modifications may help.
[Warm tips] During the treatment, in addition to maintaining vigilance and timely feedback to the doctor, patients should also follow the doctor's medication guidance and do not adjust the drug dosage or change the medication mode without permission. Maintaining good lifestyle habits and attitude, and actively cooperating with treatment, are also important factors in promoting recovery.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:[list:visits]2025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:[list:visits]2024-09-07
Lucius Pharmaceuticals Version of Vibegron Now Available1.Basic Drug InformationVibegron (generic na···【more】
Recommended:[list:visits]2026-06-08
In recent years, leveraging the World Trade Organization (WTO) patent waiver for least-developed cou···【more】
Recommended:[list:visits]2026-05-08
How Can Chinese Patients Access Generic Drugs from Laos?In recent years, generic drugs from Laos hav···【more】
Recommended:[list:visits]2026-04-08
Lucius Pharmaceuticals version of Ibrutinib is now availableIn a randomized controlled trial of 269 ···【more】
Recommended:[list:visits]2026-03-08
Leveraging the WTO patent waiver for least-developed countries (extended to 2033), Laos has seen rap···【more】
Recommended:[list:visits]2026-31-07
Alectinib Has Been Launched in LaosAlectinib is an oral targeted therapeutic drug belonging to the c···【more】
Recommended:[list:visits]2026-30-07

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643